Using a stem cell-derived therapeutic developed over more than a decade in Dr. David Gamm’s lab at UW-Madison, BlueRock Therapeutics has treated the first patient in a new Phase 1/2a clinical trial aimed at a group of …
Working Together to Understand, Protect and Restore Vision